631 SEMI-QUANTIFICATION OF ANGIOGENESIS IN UROTHELIAL CANCER OF UPPER URINARY TRACT: A COMPARISON AMONG THREE ENDOTHELIAL MARKERS

Abstract

You have accessJournal of UrologyUrothelial Cancer: Upper Tract Tumors1 Apr 2012631 SEMI-QUANTIFICATION OF ANGIOGENESIS IN UROTHELIAL CANCER OF UPPER URINARY TRACT: A COMPARISON AMONG THREE ENDOTHELIAL MARKERS Yasuyoshi Miyata, Tomohiro Matsuo, Kojiro Ohba, and Hideki Sakai Yasuyoshi MiyataYasuyoshi Miyata Nagasaki, Japan More articles by this author , Tomohiro MatsuoTomohiro Matsuo Nagasaki, Japan More articles by this author , Kojiro OhbaKojiro Ohba Nagasaki, Japan More articles by this author , and Hideki SakaiHideki Sakai Nagasaki, Japan More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2012.02.710AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Angiogenesis is the development of new blood vessels from preexisting capillaries. In numerous solid tumors, angiogenesis plays important roles for cell proliferation, progression, and survival. So, adequate method for quantification of angiogenesis is important to predict the prognosis and discuss the follow up strategy. However, there is no standard mothod of quantification of angiogenesis in urothelial cancer of upper urinary tract (UC-UUT). The purpose of this study was to evaluate the semi-quantification of angiogenesis by assessing microvessel density in UC-UUT, comparing the performance of three antibodies: anti-CD31, anti-CD34, and anti-CD105. METHODS Seventy-four patients diagnosed with UC-UUT undergoing radical operation were evaluated. There is no patient with metastasis because such UC-UUT patient was usefully treated with chemotherapy in our hospital. Formalin fixed specimens were analyzed by semi-quantitative immunohistochemical staining for CD31, CD34, and CD105. Microvessel density (MVD) “hot spots” were counted in three 200X high-power field (HPF). VEGF-A expression was also evaluated by immunohistochemical technique. Relationships between each MVD and pT stage, grade, and VEGF-A expression were evaluated. RESULTS Median MVDs estimated by anti-CD31, anti-CD34, and anti-CD105 were 48, 72, and 28/HPF, respectively. Although all MVDs were significantly associated with pT stage and grade, CD105-MVD showed most significant difference (p<0.001) between low (pTa+1) and high pT stage (pT2 - 4) compared to CD31-MVD or CD34-MVD. In addition, interestingly, CD105-MVD in tumor with pTa and Grade 1was extremely lower (median = 5/HPF) compared to that in pT1 tumors (median = 23/HPF). Such finding was not found in CD31-MVD and CD34-MVD. When relationship between each MVD and VEGF-A expression was investigated, CD105-MVD also showed most closely correlation (r=0.543, p<0.001). In survival analysis, all MVDs were associated with disease-free survival and cause-specific survival by Kaplan-Meier survival analyses. However, only CD105-MVD was identified as independent predictor for disease-free survival in multivariate analysis model including pT stage and grade. CONCLUSIONS In UC-UUT, MVD estimated by anti-CD105 antibody was most useful marker to reflect pathological status, malignant potential, and prognosis. In several cancers, CD105 was recognized as tumor-specific endothelial markers. We also suggest that CD105 is useful marker to detect tumor-specific angiogenesis in patients with UC-TCC. © 2012 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 187Issue 4SApril 2012Page: e257 Advertisement Copyright & Permissions© 2012 by American Urological Association Education and Research, Inc.MetricsAuthor Information Yasuyoshi Miyata Nagasaki, Japan More articles by this author Tomohiro Matsuo Nagasaki, Japan More articles by this author Kojiro Ohba Nagasaki, Japan More articles by this author Hideki Sakai Nagasaki, Japan More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...